Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
The carbohydrate antigen 19-9 (CA19-9) and radioimmunoassay have been shown to offer new hope for improving the diagnosis of pancreatic cancer, and various tumor markers (including SPan-1, DUPAN-2, and CA50) have been established. While clinical studies of these markers have found satisfactory sensitivities, only a few studies have compared these tumor markers on the same blood samples. We therefore evaluated the clinical efficacy of SPan-1, CA19-9, DUPAN-2, CA50, carcino-embryonic antigen, and Elastase 1 in detecting pancreatic cancer in identical blood samples.
Satake
K
K
First Department of Surgery, Osaka City University Medical School, Japan.
Takeuchi
T
T
D000951:Antigens, Neoplasm / Q000097:blood; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D006801:Humans; D010196:Pancreatic Elastase / Q000097:blood; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D011863:Radioimmunoassay; D012680:Sensitivity and Specificity
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; C042317:DU-PAN-2 antigen, human; C059729:pancreatic associated antigen, SPan-1; D010196:Pancreatic Elastase